

# Michael W Fried

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11503401/michael-w-fried-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147  
papers

19,085  
citations

54  
h-index

138  
g-index

156  
ext. papers

20,967  
ext. citations

8.1  
avg. IF

6.24  
L-index

#	Paper	IF	Citations
147	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , <b>2021</b> , 3, 196-208	1	
146	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1042-1056	3.4	2
145	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , <b>2021</b> , 73, 2124-2140	11.2	8
144	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , <b>2021</b> , 73, 1637-1651	11.2	4
143	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , <b>2021</b> , 41, 692-704	7.9	2
142	"If I Get Cured, My Whole Quality of Life Will Change": Patients Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	3
141	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , <b>2021</b> , 74, 2952-2964	11.2	0
140	Linkage of resistance-associated substitutions in GT1 sofosbuvir NS5A inhibitor failures treated with glecaprevir/pibrentasvir. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 820-828	13.4	1
139	Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 457-468	6.1	5
138	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 540-548	13.4	45
137	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 1011-1020	4	8
136	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH)". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 592-593	13.4	
135	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , <b>2020</b> , 71, 1894-1909	11.2	11
134	Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients awaiting a liver transplant". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 985-986	13.4	
133	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , <b>2020</b> , 72, 1819-1837	11.2	12
132	Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy. <i>BMC Infectious Diseases</i> , <b>2020</b> , 20, 632	4	0
131	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 259-261	6.9	1

130	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221683	3.7	29
129	Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz175	1	3
128	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 486-497	13.4	27
127	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 856-865	3.4	11
126	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2541-2551.e2	6.9	15
125	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1388-1399	6	5
124	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , <b>2019</b> , 157, 1506-1517.e1	13.3	19
123	Real-World Evidence and Hepatitis C. <i>Topics in Medicinal Chemistry</i> , <b>2019</b> , 411-427	0.4	
122	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1811-1819.e4	6.9	16
121	A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , <b>2018</b> , 2, 484-491	6	6
120	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , <b>2018</b> , 2, 354-363	6	9
119	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , <b>2018</b> , 8, 3199	4.9	14
118	An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 254-260	11.6	16
117	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 72, 73-85	2.3	6
116	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C. <i>Pilot and Feasibility Studies</i> , <b>2018</b> , 4, 92	1.9	4
115	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196908	3.7	16
114	Chronic hepatitis B virus mono-infection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 622-628	3.4	2
113	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. <i>Hepatology</i> , <b>2018</b> , 67, 1253-1260	11.2	97

112	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , <b>2017</b> , 66, 389-397	11.2	147
111	Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. <i>Contemporary Clinical Trials Communications</i> , <b>2017</b> , 6, 85-96	1.8	3
110	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , <b>2017</b> , 66, 1090-1101	11.2	127
109	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , <b>2017</b> , 57, 58-68	2.3	10
108	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , <b>2017</b> , 66, 1844-1852	19.2	54
107	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 700-707	13.4	8
106	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 356-366	3.8	7
105	American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. <i>Gastroenterology</i> , <b>2017</b> , 152, 1578-1587	13.3	53
104	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 637-648	8	383
103	Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. <i>Clinical Liver Disease</i> , <b>2017</b> , 10, 87-92	2.2	1
102	What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment. <i>Patient</i> , <b>2017</b> , 10, 335-344	3.7	8
101	High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. <i>Liver International</i> , <b>2016</b> , 36, 344-52	7.9	2
100	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , <b>2016</b> , 151, 1131-1140.e5	13.3	166
99	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 776-783	11.6	37
98	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , <b>2016</b> , 36, 807-16	7.9	217
97	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 684-695.e5	13.3	126
96	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , <b>2016</b> , 150, 419-29	13.3	140
95	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , <b>2016</b> , 22, 24-33	4.5	96

94	Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. <i>Infection Control and Hospital Epidemiology</i> , <b>2016</b> , 37, 140-2	2	3
93	Treatment options of patients with chronic hepatitis C who have failed prior therapy. <i>Clinical Liver Disease</i> , <b>2016</b> , 7, 40-44	2.2	6
92	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , <b>2016</b> , 36, 488-502	7.9	4
91	Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 336-44	3	6
90	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , <b>2015</b> , 35, 2358-62	7.9	14
89	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , <b>2015</b> , 64, 1824-33	19.2	99
88	Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 183-92	6.9	68
87	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , <b>2015</b> , 64, 948-56	19.2	90
86	Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 286-93	13.4	74
85	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. <i>Liver International</i> , <b>2015</b> , 35, 1886-92	7.9	13
84	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , <b>2015</b> , 149, 649-59	13.3	622
83	Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1879-88	59.2	975
82	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. <i>Gastroenterology</i> , <b>2014</b> , 146, 430-41.e6	13.3	193
81	Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6079-92	5.9	28
80	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 384, 403-13	40	394
79	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 1073-82	2.2	42
78	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. <i>Hepatology</i> , <b>2013</b> , 58, 1918-29	11.2	233
77	A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , <b>2013</b> , 57, 1325-32	11.2	80

76	Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , <b>2013</b> , 81, 361-74	6.5	21
75	Randomized study of asunaprevir plus pegylated interferon- $\alpha$ and ribavirin for previously untreated genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 885-93	1.6	43
74	Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. <i>PLoS ONE</i> , <b>2013</b> , 8, e69698	3.7	11
73	Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. <i>Gastroenterology</i> , <b>2012</b> , 142, 1314-1323.e1	13.3	46
72	Unexpected maintenance of hepatitis C viral diversity following liver transplantation. <i>Journal of Virology</i> , <b>2012</b> , 86, 8432-9	6.6	18
71	Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. <i>Clinical Liver Disease</i> , <b>2012</b> , 1, 95-97	2.2	3
70	Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1469-74	4	31
69	Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1439-44	4	14
68	Barriers to hepatitis C treatment. <i>Liver International</i> , <b>2012</b> , 32 Suppl 1, 151-6	7.9	122
67	Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 274-82	27.4	103
66	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. <i>Clinical Trials</i> , <b>2012</b> , 9, 102-12	2.2	12
65	Hepatitis C virus: a critical appraisal of new approaches to therapy. <i>Hepatitis Research and Treatment</i> , <b>2012</b> , 2012, 138302		4
64	Response-guided telaprevir combination treatment for hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1014-24	59.2	618
63	Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , <b>2011</b> , 71, 349-56	4.1	16
62	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 69-75	13.4	137
61	The role of triple therapy in HCV genotype 1-experienced patients. <i>Liver International</i> , <b>2011</b> , 31 Suppl 1, 58-61	7.9	9
60	Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment. <i>Liver International</i> , <b>2011</b> , 31, 903-4	7.9	
59	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , <b>2011</b> , 53, 32-41	11.2	123

58	Quantitation of pretreatment serum interferon-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. <i>Hepatology</i> , <b>2011</b> , 53, 14-22	11.2	86
57	Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 2182-90	4	37
56	A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1777-86	0.7	54
55	Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 434-49	2.9	102
54	Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. <i>Gastroenterology</i> , <b>2010</b> , 139, 1181-9	13.3	156
53	Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1794-8	4	14
52	Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2949-58	0.7	45
51	Hepatitis C virus: a critical appraisal of approaches to therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 397-414; quiz 366	6.9	16
50	Hepatitis C infection with normal liver chemistry tests. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 503-5	6.9	5
49	Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1981-8	0.7	48
48	The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 1909-16	4	67
47	Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 65-72	4	134
46	Hepatitis C: current options for nonresponders to peginterferon and ribavirin. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 53-9	5	3
45	HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , <b>2008</b> , 47, 428-34	11.2	178
44	R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. <i>Hepatology</i> , <b>2008</b> , 48, 385-97	11.2	92
43	Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. <i>Hepatology</i> , <b>2008</b> , 48, 1033-43	11.2	59
42	High relapse rate seen at week 72 for patients treated with R1626 combination therapy. <i>Hepatology</i> , <b>2008</b> , 48, 1349-50	11.2	17
41	Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. <i>Gastroenterology</i> , <b>2007</b> , 132, 733-44	13.3	94

40	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , <b>2007</b> , 46, 1548-63	11.2	218
39	High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 3251-8	4	43
38	Assessing the validity of self-reported medication adherence in hepatitis C treatment. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1116-23	2.9	48
37	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 247-55	2.4	41
36	Optimizing treatment regimens in hepatitis C. <i>Clinics in Liver Disease</i> , <b>2006</b> , 10, 835-50	4.6	13
35	Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. <i>Gastroenterology</i> , <b>2006</b> , 131, 470-7	13.3	405
34	Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance. <i>Gastroenterology</i> , <b>2006</b> , 131, 757-64	13.3	16
33	Social stigmatization and hepatitis C virus infection. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 220-43		70
32	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2682-95	59.2	1226
31	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 425-33	13.4	425
30	Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. <i>Liver Transplantation</i> , <b>2005</b> , 11, 1235-41	4.5	58
29	Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. <i>Seminars in Liver Disease</i> , <b>2004</b> , 24 Suppl 2, 47-54	7.3	61
28	Guidelines for stopping therapy in chronic hepatitis C. <i>Current Gastroenterology Reports</i> , <b>2004</b> , 6, 17-21	5	16
27	Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 1298-305	0.7	66
26	Viral factors affecting the outcome of therapy for chronic hepatitis C. <i>Reviews in Gastroenterological Disorders</i> , <b>2004</b> , 4 Suppl 1, S8-S13		5
25	Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 140-5	4	19
24	Hepatitis C and Alcohol: Fundamental and Translational Research Directions. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2003</b> , 27, 726-731	3.7	11
23	Current therapy for hepatitis C: pegylated interferon and ribavirin. <i>Clinics in Liver Disease</i> , <b>2003</b> , 7, 149-61	1.6	94



22	Side effects of therapy for chronic hepatitis C. <i>Gastroenterology</i> , <b>2003</b> , 124, 1711-9	13.3	212
21	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 106-11	13.4	41
20	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , <b>2002</b> , 36, S237-S244	11.2	428
19	Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. <i>Hepatology</i> , <b>2002</b> , 36, 967-72	11.2	53
18	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , <b>2002</b> , 36, S237-44	11.2	337
17	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 975-82	59.2	5551
16	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <i>Journal of Hepatology</i> , <b>2002</b> , 37, 500-6	13.4	337
15	Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. <i>Hepatology</i> , <b>2001</b> , 33, 433-8	11.2	269
14	Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 749-55	13.4	138
13	Advances in therapy for chronic hepatitis C. <i>Clinics in Liver Disease</i> , <b>2001</b> , 5, 1009-23	4.6	10
12	Internal biliary stenting in orthotopic liver transplantation. <i>Liver Transplantation</i> , <b>2000</b> , 6, 356-61	4.5	23
11	A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3225-9	0.7	49
10	Diagnostic testing for hepatitis C: practical considerations. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 31S-35S	2.4	11
9	Management of hepatitis C in the hemophilia patient. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 85S-89S	2.4	285
8	Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. <i>Liver Transplantation</i> , <b>1998</b> , 4, 128-32		74
7	Clinical application of hepatitis C virus genotyping and quantitation. <i>Clinics in Liver Disease</i> , <b>1997</b> , 1, 631-46	4.6	9
6	Therapy of chronic viral hepatitis. <i>Medical Clinics of North America</i> , <b>1996</b> , 80, 957-72	7	19
5	Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1099-105	59.2	518

- 4 Therapy of chronic hepatitis B with a 6-month course of ribavirin. *Journal of Hepatology*, **1994**, 21, 145-50 3.4 33
- 3 Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. *Digestive Diseases and Sciences*, **1993**, 38, 631-6 4 72
- 2 A pilot study of ribavirin therapy for chronic hepatitis C. *Hepatology*, **1992**, 16, 649-54 11.2 258
- 1 A pilot study of 2-CDideoxyinosine for the treatment of chronic hepatitis B. *Hepatology*, **1992**, 16, 861-4 11.2 37